Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer expands NicOx alliance

March 6, 2006 | A version of this story appeared in Volume 84, Issue 10

In a deal valued at up to $356 million, NicOx has granted Pfizer exclusive rights to use its nitric oxide-donating technology for the discovery and development of ophthalmology products. In the first year of the pact, Pfizer will make a $27 million payment to NicOx, which includes an $18 million stake in the French biotech firm. Each year thereafter, NicOx will receive another $3.6 million in research funding, in addition to possible milestone payments and royalties. The deal builds on an existing relationship between the companies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.